Eli Lilly and Company (NYSE:LLY) Trading Up 0.3%

Shares of Eli Lilly and Company (NYSE:LLY) were up 0.3% on Thursday . The company traded as high as $913.82 and last traded at $907.90. Approximately 466,320 shares traded hands during trading, a decline of 85% from the average daily volume of 3,009,589 shares. The stock had previously closed at $904.97.

Analyst Ratings Changes

LLY has been the topic of several analyst reports. Guggenheim raised their target price on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a report on Friday, August 16th. BMO Capital Markets boosted their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Evercore ISI raised Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Barclays lifted their price target on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a report on Wednesday, July 10th. Finally, Bank of America raised their target price on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $977.35.

Eli Lilly and Company Price Performance

The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The company has a market capitalization of $876.01 billion, a PE ratio of 135.75, a P/E/G ratio of 2.79 and a beta of 0.42. The company’s 50-day simple moving average is $895.06 and its 200-day simple moving average is $837.89.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The firm had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th were issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.56%. The ex-dividend date of this dividend was Thursday, August 15th. Eli Lilly and Company’s payout ratio is currently 76.58%.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 1,441 shares of Eli Lilly and Company stock in a transaction on Friday, June 28th. The shares were sold at an average price of $915.02, for a total value of $1,318,543.82. Following the transaction, the insider now directly owns 97,367,369 shares in the company, valued at approximately $89,093,089,982.38. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold 442,229 shares of company stock worth $410,002,456 over the last 90 days. 0.13% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Eli Lilly and Company

A number of hedge funds have recently added to or reduced their stakes in the company. Capital Planning LLC acquired a new stake in shares of Eli Lilly and Company in the 1st quarter valued at approximately $262,000. CHURCHILL MANAGEMENT Corp purchased a new position in Eli Lilly and Company in the first quarter worth $6,916,000. M&G Plc purchased a new stake in shares of Eli Lilly and Company during the 1st quarter worth $8,896,000. IPG Investment Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth $351,000. Finally, HighPoint Advisor Group LLC acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth $9,878,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.